[7]
Adams J, Ma Y-T, Stein R, Baevsky M, Grenier L, Plamondon L. Boronic ester and acid compounds, synthesis and uses. WO9613266, 1996.
[8]
Pickersgill IF, Bishop J, Koellner C, et al. Synthesis of peptidyl boronic acids and esters. WO2005097809, 2005.
[9]
Palle RV, Kadaboina R, Murki V, et al. Preparation of bortezomib in crystalline form. WO2009036281, 2009.
[10]
Zhao J, Du Y, Zhao Y, Cai K, Wu C, Yang J. Manufacture method of high optical purity bortezomib and its intermediate. CN103304629, 2013.
[11]
Rao DR, Kankan RN, Pathi SL, Puppala R. Lawrence Louis Process for preparing of bortezamib. WO2014041324, 2014.
[12]
Dhar DS, Kamlesh SK, Dnyaneshwar NS. An improved process for preparation of bortezomib. IN972/MUM/2013 2015.
[13]
Zhao X, Li X, Zhao Y. Synthesis method of high-purity bortezomib and its intermediates. CN103012551, 2013.
[14]
Zou Y, Huang Q, Jiang X, Tang Y, Zou C, Yuan Q. Impurity of bortezomib and preparation method thereof. CN109134601, 2019.
[15]
Ravi JRR, Pulla Reddy M, Adibatla Kali Satya BR, Benkaiah Chowdary N. Polymorphic forms of bortezomib and process for their preparation. WO2008075376, 2008.
[16]
Reddy BP, Reddy KR, Reddy DM, Reddy RR, Ramachandra P, Krishna BV. Polymorphs of bortezomib. WO2011099018, 2011.
[17]
Jamjanam SR, Moturu VRM, Dammalapati VLNR, Gorantla SR. Preparation of a novel crystalline form of bortezomib and pharmaceutical composition thereof. WO2012131707, 2012.
[18]
Xie T, Xu Z, Zhou H, Chen F. One kind of bortezomib crystal form, and its preparation method, pharmaceutical compositions and application in antitumor drugs. CN104693271, 2015.
[19]
Son HJ, Park YK, Kim Y-M, Hwang J-M, Kim JH. Novel crystalline form of bortezomib and preparation method thereof. WO2015122702, 2015.
[20]
Ding J, Xu W, Zhuang X, Chen X. Dextran-bortezomib conjugate medicine and its preparation method. CN104958768, 2015.
[21]
Shrawat VK. A process for the preparation of crystalline bortezomib. WO201407613, 2014.
[22]
Ravi JRR, Kondaveeti S, Adibhatla KSBR, Muddasani PR, Nannapaneni VC. Stable and pure polymorphic form of bortezomib. WO2014097306, 2014.
[23]
Shivakumar P, Ramakrishnaiah S, Alampalli B, Chaturvedi A. Bortezomib injection formulations. WO2014102755, 2014.
[24]
Joo SH. Stable crystalline form bortezomib. KR101741403, 2016.
[25]
Furuya T, Abe M. Manufacturing method for bortezomib crystals. WO2019151133, 2019.
[26]
Farag SS. Combined use of bendamustine, doxorubicin and bortezomib for the treatment of multiple myeloma. WO2010056733, 2010.
[27]
Shaughnessy JD Jr, Barlogie B, Qu P. Uses of bortezomib in predicting survival in multiple myeloma patients. WO2010078531, 2010.
[28]
Liu X, Li X, Qin Q, Gao C, Yu X. Pharmaceutical use of a dicycloplatin (DCP) for the prophylaxis or treatment of proliferative diseases. WO2016172393, 2016.
[29]
Won PJ, Park WJ. Composition for relief and treatment of liver injury comprising bortezomib as a active ingredient. KR101695237, 2017.
[30]
Kim NS, Park J-S, Yi J-M, et al. Composition, containing Lithospermum erythrorhizon extract as active ingredient, for preventing, alleviating, or treating peripheral neuropathy. WO2016182139, 2016.
[31]
Chen T, Shachar Y. Intratumoral delivery of bortezomib into brain tumor by pump implanted in brain. WO2019148181, 2019.
[32]
Xie H, Cakana A. Methods of treating multiple myeloma. US20190298827, 2019.
[33]
Gupta S. Lyophilized formulation of sugar-containing boronic acid compounds. WO2002059130, 2002.
[34]
Plamondon L, Grenier L, Adams J, Gupta SL. Lyophilized formulation of boronic acid compounds. WO2002059131, 2002.
[35]
Zalipsky S, Martin F. Liposomal formulation of bortezomib (PS-341). WO2006052733, 2006.
[36]
Sun L, Sun Z, Zhang W. Antitumor sustained-release injection containing taxol and bortezomib. CN101301472, 2008.
[37]
Hou H, Sun Q, Sun Z. Bortezomib and alkylating agent composite sustained-release injection with drug delivery delayed greatly and preparation method thereof. CN101336926, 2009.
[38]
Mao H, Wang M, Chen Y. Antitumor sustained-release injection containing bortezomib and topoisomerase inhibitors. CN101336893, 2009.
[39]
Soppimath K, Pejaver S, Patel KR, et al. Stable bortezomib formulations. WO2011116286, 2011.
[40]
Usayapant A, Bowman D. Bortezomib formulations stabilized with boric. WO2012047845, 2012.
[41]
Xia F. Pharmaceutical composition containing bortezomib for treating T cell lymphoma. CN103191405, 2013.
[42]
Zhao J, Cai J, Zong Z, Ji T, Jia Y. Bortezomib lyophilized composition and preparation method thereof. CN103446068, 2013.
[43]
Yeon WK, Wook KD, Pyo HE. Oral pharmaceutical composition comprising bortezomib. KR20140057048, 2014.
[44]
Puppala R, Pathi SL, Rao DR, Kankan RN. Process for the preparation of bortezomib mannitol ester substantially free of the degradation impurity. WO2014170628, 2014.
[45]
Zhong Z, Chen Y, Wang X, Ma Y. Bortezomib medicinal composition and preparation method thereof. CN103212055, 2013.
[46]
Chen Q, Zong Z, Jia Y. Bortezomib lyophilized composition and its preparation method. CN103070835, 2013.
[47]
Zaludek B. Pharmaceutical compositions comprising bortezomib. WO2015025000, 2015.
[48]
Yuan S, Yang X, Wang L, et al. Method for preparing bortezomib powder for injection. CN103505424, 2014.
[49]
Shivakumar P, Ramakrishnaiah S, Alampalli B, Chaturvedi AK. Bortezomib formulations. WO2016059515, 2016.
[50]
Yao Z, Luo Y, Yan F, Zhang H, Che B. Pharmaceutical composition containing bortezomib and preparation method thereof. CN105056205, 2015.
[51]
Shaik RA, Chaurasiya A, Saha A, Patel BV, Bhagwatwar H, Pillai SA. Stable liquid ready-to-use injectable formulation of bortezomib. WO2016001905, 2016.
[52]
Pasqua L, Leggio A, Liguori A, Morelli C, Ando S. Bortezomib-based delivery system. WO2016174693, 2016.
[53]
Chen Z, Zheng Q, Wang S, Zhao X. Bortezomib injection agent and preparation method thereof. CN105496960, 2016.
[54]
Shivakumar P, Dasari N, Kulkarni R, Chaturvedi AK. Bortezomib pharmaceutical formulations comprising orthophosphoric acid for treating cancer. WO2016059515, 2016.
[55]
Mudri D, Vince N. Malic acid esters of bortezomib. EP3031811, 2016.
[56]
Gondaliya DP, Gurjar MK, Mehta SS, Patel HP, Patel HI, Patel NM. Pharmaceutical composition of bortezomib. WO2016110870, 2016.
[57]
Sun J, Wang Y, Wu Z. Bortezomib sustained-release preparation and its preparation method. CN103656668, 2014.
[58]
Jae PW, Won PJ. Composition for preventing or treating obesity or non-alcoholic fatty liver, containing bortezomib. KR20160117839 2016.
[59]
Chandrashekhar K, Nagaraju B. Stable liquid pharmaceutical compositions of bortezomib. WO2016166653, 2016.
[60]
Zhang G, Zhao Z, Cheng Z. A kind of bortezomib lyophilized powder injection and the production method thereof. CN104546744, 2015.
[61]
Yuan H, Wang Y, Dong L, Sun Y, Sun C. Lyophilized preparation of bortezomib and preparation method thereof. CN106176637, 2016.
[62]
Sun Y, Wang Y, Dong L, Huang Y, Yuan H. Bortezomib freeze-dried powder injection and its making process. CN106309385, 2017.
[63]
Schridde E. Ready-to-use bortezomib solution. WO2017013208, 2017.
[64]
Kanteepan P, Vekariya SL, Mandal JK, Mehta SP. Composition comprising bortezomib. US10314880, 2017.
[65]
Katori K, Kinoshita M, Isane M, Inoue H. Freeze-dried compositions containing bortezomib and tartaric acid prepared for reconstitution of pH-controlled pharmaceutical infection solution. JP2017057202, 2017.
[66]
Ebetino F, Boeckman R, Xing L, Xiao L, Boyce B. Bortezomib conjugates and methods using same. WO2017079262, 2017.
[67]
Lu W, Wang X, Xie C, Wei G, Hu X. Bortezomib water-soluble medicinal composition and preparation method and application method thereof to antitumor agents. CN107224569, 2017.
[68]
Liu C, Zhuang H, Wang Y, et al. Bortezomib pharmaceutical composition for injection. CN103142509, 2013.
[69]
Aydinlar T. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex for use in treatment of cancers such as multiple myeloma and mantle cell lymphoma. WO2018038687, 2018.
[70]
Lee JH, Cho TK, Ryu CY, Cho YD. Stable preparation containing bortezomib and preparation method therefor. WO2018164513, 2018.
[71]
Kharbanda S, Shukla V, Kufe D, Singh H. Polymeric nanoparticles and antitumor uses thereof. WO2018085407, 2018.
[72]
Gan Y, Zhu Q, Zhu C, Ji L, Jin Y, Guo S. Bortezomib pharmaceutical composition and applications thereof. WO2018108164, 2018.
[73]
Zhao Z, Hao G, Shao J, Fan F, Wu S. Bortezomib freeze-dried powder injection and preparation method thereof. CN104414982, 2015.
[74]
Nazarenko AB, Kinasov DG, Ladygin VV, Kornev KO, Zakoryukin NV. Bortezomib lyophilizate production method and a bortezomib-containing pharmaceutical composition in the form of stable lyophilizated product produced by said method. RU2659160, 2018.
[75]
Yoshioka Y, Fujiki D. Bortezomib liquid preparation comprising propylene glycol and ascorbic acid compound. JP2018168088, 2018.
[76]
Hidaka A, Motoyama J. Preparation of pharmaceutical composition containing bortezomib. JP2018177649A, 2018.
[77]
Hou L. Bortezomib phosphatide complex and preparation method and application thereof. CN109045272, 2018.
[78]
Sun C, Wang X, Yuan H, Sun Y, Meng W. Bortezomib pharmaceutical composition and preparation method thereof. CN106265536, 2017.
[79]
Li N, Wang J, Li F. Bortezomib lyophilized powder for injection and its preparation method. CN109364030, 2019.
[80]
Kwang KK, Eun KY. Composition for preventing, improving or treating atopic skin diseases containing proteasome inhibitor as active ingredient. KR101953671, 2019.
[81]
Li N, Gui J, Shi X. Freeze-drying process of bortezomib freeze-dried powder for injection. CN109453125, 2019.
[82]
Jae PW, Keun PI. Composition comprising bortezomib or its pharmaceutically acceptable salt as active ingredient for inhibiting multidrug resistance. KR20190027148, 2019.
[83]
Kharbanda S, Singh H. Polymeric nanoparticles comprising bortezomib. WO2019104001, 2019.
[84]
Hattori H. Lyophilized pharmaceutical composition comprising bortezomib. JP2019085338, 2019.
[85]
Serda RE, Noureddine A. A high capacity platform for immunogenic cancer cell death using siliceous nanoparticles comprising TLR ligand or other immunostimulant. WO2019173391, 2019.
[86]
Mandal JK, Mehta SP. Composition comprising bortezomib. US20190290718, 2019.